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Abstract Proton pump inhibitors (PPIs) have become
some of the most frequently prescribed medications for
treatment of adults and children. Their effectiveness for
treatment of peptic conditions in the pediatric population,
including gastric ulcers, gastroesophageal reflux disease
(GERD), and Helicobacter pylori infections has been
established for children older than 1 year. Studies of the
preverbal population of neonates and infants have identi-
fied doses that inhibit acid production, but the effectiveness
of PPIs in the treatment of GERD has not been established
except for the recent approval of esomeprazole treatment of
erosive esophagitis in infants. Reasons that have been
proposed for this are complex, ranging from GERD not
occurring in this population to a lack of histologic identi-
fication of esophagitis related to GERD to questions about
the validity of symptom scoring systems to identify
esophagitis when it occurs in infants. The effectiveness of
PPIs relates to their structures, which must undergo acidic
activation within the parietal cell to allow the PPI to be
ionized and form covalent disulfide bonds with cysteines of
the H?–K?-adenosine triphosphatase (H?–K?-ATPase).
Once the PPI binds to the proton pump, the pump is
inactivated. Some PPIs, such as omeprazole and rabep-
razole bind to cysteines that are exposed, and their binding
can be reversed. After irreversible chemical inhibition of
the proton pump, such as occurs with pantoprazole, the
recovery of the protein of the pump has a half-life of
around 50 h. Cytochrome P450 (CYP) 2C19 and to a lesser
degree CYP3A4 clear the PPIs metabolically. These
enzymes are immature at birth and reach adult levels of
activity by 5–6 months after birth. This parallels studies of
the maturation of CYP2C19 to adult levels by roughly the
same age after birth. Specific single nucleotide polymor-
phisms of CYP2C19 reduce clearance proportionally and
increase exposure and prolong proton pump inhibition.
Prolonged treatment of pediatric patients with PPIs has not
caused cancer or significant abnormalities.
1 Introduction
Treatment of all ages of pediatric patients with proton
pump inhibitors (PPIs) has expanded dramatically during
the last 3 decades as concerns about peptic acid diseases in
adults and children have increased. Based on data from
four geographically diverse commercial healthcare claims
databases including 12.9 million members and 1,308,126
infants\12 months of age, prescriptions for PPIs increased
7.5-fold from 1999 to 2004 [1]. PPIs gained popularity for
acid suppression because they inhibit the last step in gastric
acid secretion regardless of the stimulus for acid secretion
and can be dosed once a day in most patients. Effective
treatment with PPIs requires an understanding of the
physiology of gastric acid secretion, the need for activation
of the PPI for it to bind to the proton pump and cause
inactivation, the pharmacokinetics of PPIs, the pharmaco-
genetics of PPIs, and the results of pharmacodynamics
studies of PPIs. This paper will cover those aspects of PPIs
in the pediatric population.
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1.1 Physiology of Gastric Acid Secretion
The pharmacodynamics and pharmacokinetics of PPIs are
integrally linked to the physiology and structure of the
enzyme responsible for gastric acid secretion by the pari-
etal cell, the H?–K?-adenosine triphosphatase (H?–K?-
ATPase). This extraordinary acid pump creates a 1 million-
fold gradient in H? concentration from inside the parietal
cell to the gastric lumen in return for inward transport of
K? [2]. Without stimulation, the H?–K?-ATPase enzyme
resides in the parietal cell cytoplasm in a relatively inactive
tubulovesicle form, as diagrammed by Litalien et al. [3] in
Fig. 1. This ATPase can be stimulated to secrete gastric
acid by the binding of different ligands, such as acetyl-
choline, histamine, or gastrin [4]. Histamine can be
released by the enterochromaffin-like cells directly or after
stimulation of these cells by gastrin, which is released after
a meal. Histamine then binds to the histamine H2 receptor
and stimulates the H?–K?-ATPase to release intracellular
second messengers, cyclic adenosine monophosphate
(cAMP), and Ca2?, leading to acid release.
Regardless of the stimulus, gastric acid secretion occurs
through a single common pathway after activation by
ligand binding (Fig. 1) [3–5]. Secretion of acid into the
gastric lumen requires a conformational change in the H?–
K?-ATPase to exchange H? for K? on the enzyme while
basolateral secretion of HCO3
- maintains intracellular
electroneutrality. After ligands bind to the parietal cell and
activate intracellular second messengers, H?–K?-ATPase
binds magnesium adenosine 50-triphosphate (MgATP),
which provides the energy to fuse with the apical microvilli
on the luminal membrane of the parietal cell’s expanded
secretory canaliculus [2, 6–8]. This ATPase binds hydro-
nium (H3O
?) internally with the enzyme in the E1 position
while K? is bound in the lumen. As K? binds, Pi is
released internally, which changes the enzyme to an E2K
formation from which K? cannot be easily released.
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Fig. 1 General chemical structure and mechanism of action of proton
pump inhibitors (PPIs). Reproduced from Litalien et al. [3], with
permission from Springer International Publishing AG ( Adis Data
Information BV [2005]. All rights reserved.) ATPase adenosine
triphosphatase, CYP cytochrome P450, P-gp P-glycoprotein, pKa
negative logarithm of the acid ionization constant
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the H3O
? is now in the lumen. To maintain an adequate
supply of K? in the lumen requires K? transport, which
occurs through the KCNQ1 channel, a voltage-gated
potassium channel originally associated with the Long QT
syndrome. For the KCNQ1 channel to transport potassium,
its KCNE2 subunit must function at pH 1 on the extra-
cellular side of the parietal cell where acid is being trans-
ported. In this extremely acidic environment, the channel is
activated by the acid, loses its gating function, and remains
open. To balance the secretion of H? from the parietal cell
into the gastric lumen, HCO3
- is secreted from the baso-
lateral portion of the cell, which prevents the cell from
developing a negative charge.
1.2 Structure of the H?–K?-ATPase Enzyme, Parietal
Cell Proton Pump
The H?–K?-ATPase must be activated to the microvilli
location for the PPI to bind and cause inactivation, and the
enzyme’s structure is a key element of that inactivation
(Fig. 1). The gastric H?–K?-ATPase belongs to the P2
family of ATPases and, like the extensively studied Na?–
K?-ATPase, is a heterodimer with an alpha and beta subunit
[7, 9]. Like Na?–K?-ATPase, the H?–K?-ATPase alpha
subunit contains 1,033 amino acids in a heterodimer con-
figuration with ten transmembrane or membrane-inserted
segments (TMs). A cluster of carboxylic amino acids in the
intra-membrane segments of TM4–6 and TM8 help to form
the ion binding domain [5, 10]. The alpha subunit is highly
conserved, with 98 % homology among enzymes from the
hog, rabbit, dog, and human [6]. The smaller beta subunit
contains 190 amino acids, with its N-terminus in the cyto-
plasm. This beta subunit includes only one transmembrane
segment with 6 or 7 external N-linked glycosylation sites
that are important for the structure of the enzyme and the
conformational changes involved in acid secretion. This
ATPase contains 28 cysteine (CYS) molecules, ten of which
are accessible for binding by activated PPIs [5, 11]. These
CYSs are located at different regions of the enzyme, some
within the proton transporting portions (CYS321, 813, and
822) and others outside the proton pump on the luminal side
of the enzyme (CYS892) [5, 12]. The locations are impor-
tant to the reversibility of the binding of the PPIs and their
pharmacodynamics.
1.3 Activation of the Proton Pump Inhibitors (PPIs)
for Binding to the H?–K?-ATPase
PPIs must be activated to bind to the CYSs of the ATPase,
and the rate of this activation varies with their structures
[5]. These PPIs are weak bases that are acid labile and must
be formulated with an enteric coating to resist gastric acid
degradation and allow absorption in the more alkaline
environment of the small intestine. Currently approved
PPIs have a very similar basic structure that combines a
benzimidazole ring and a pyridine ring through a sulfinyl
linkage as shown in Fig. 1 [12]. The first PPI discovered
was timoprazole, which lacked any substitutions on these
rings in contrast to currently approved PPIs with various
substitutions that affect their chemistry. For the sulfinyl to
chemically bind to the CYSs of the ATPase, it has to gain
energy from the acidic environment inside the parietal cell
[5].
Activation of the PPI occurs by addition of two protons
to the nitrogens on either side of the sulfinyl group (Fig. 1)
[5, 6]. Once it is activated, the PPI can inactivate the proton
pump by binding to CYS molecules on the ATPase to form
disulfide bonds. The chemistry of these reactions has been
thoroughly described by Roche [5] and Shin et al. [6]. The
PPIs have two pKa (negative logarithm of the acid ioni-
zation constant) values that influence their activation
(Table 1; Fig. 1) [3, 5, 12]. The first pKa ranges from 3.83
to 4.53 and leads to ionization and accumulation in the
acidic region of the parietal cell canaliculus where acid is
being secreted, with pH around 1.0. This is the most acidic
cytoplasm of any cell within the body [12]. The second
pKa of approved drugs ranges from 0.11 to 0.79. This
second protonation on the benzimidazole causes rear-
rangement of the sulfinyl into a cationic sulfenic acid or a
sulfenamide, which has the energy to react with the cys-
teine sulfhydryls to form one or more covalent disulfide
bonds (Fig. 1) [3, 4].
Table 1 Chemical properties and the presence (indicated by ?) of specific cysteine (CYS) binding sites of proton pump inhibitors [3, 5, 12]
Proton pump inhibitor pKa1 pKa2 CYS321 CYS813 CYS822 CYS892
Omeprazole 4.06 0.79 ? ?
Lansoprazole 3.83 0.62 ? ?
Pantoprazole 3.83 0.11 ? ?
Rabeprazole 4.53 0.62 ?
Tenatoprazole 4.04 -0.12 ? ?
Not enough pharmacokinetic data on esomeprazole could be obtained for inclusion in the table
pKa negative logarithm of the acid ionization constant
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The PPI can bind to several different CYSs on the
proton pump. The speed with which these two activation
reactions occur influences which CYS(s) it will bind [3, 5].
All the PPIs bind to CYS813 located on the acidic luminal
side within the proton transporter, which stops proton
transfer. This location is easily accessible to the PPIs for
binding, but it is also accessible to reducing agents, such as
glutathione and dithiothreitol, which can release the PPI
and reactivate the transporter [12]. In contrast, the CYS at
position 822 located deep within the sixth transmembrane
segment of the ATPase reacts with the PPIs that are acti-
vated more slowly, such as pantoprazole and tenatoprazole.
CYS822 is relatively inaccessible to reducing agents so the
disulfide bonds created by the PPI permanently inactivate
the proton pump [12]. This difference in binding sites
accounts for some of the dynamic differences among PPIs
according to those with reversible binding and those that
are inaccessible to reduction of the disulfide bonds. Before
inactivation of the proton pump can occur, the PPI must
reach the acidic site of action within the parietal cell while
the proton pump is active for it to undergo the acidic
activation described above. The concentration at the site of
action is determined by the PPI’s pharmacokinetics,
beginning with absorption in an inactive form, distribution,
metabolism by cytochrome P450 (CYP) 2C19 or CYP3A4,
and elimination. The rate of metabolism is under devel-
opmental as well as genetic control, which confounds
accurate prediction of these rates.
2 Pharmacokinetics and the Disposition of PPIs
in Infants and Children
2.1 Biotransformation
As previously reviewed by Gibbons and Gold [4], all of the
PPIs are polyfunctional substrates for a variety of phase I
and phase II drug metabolizing enzymes. The relative
contribution of these enzymes to the biotransformation of
omeprazole, lansoprazole, rabeprazole, and pantoprazole is
illustrated in Fig. 2. Of the four predominantly used PPIs
within this class, two different CYP isoforms are respon-
sible for the majority of their biotransformation: CYP2C19
and CYP3A4 [4]. In contrast, the metabolism of ilaprazole,
a new PPI, is also catalyzed by CYP3A5 [13], which along
with CYP3A4, is predominantly located in the liver and
small intestine. While functionally important polymorphic
expression has been described for both CYP3A4 and
CYP3A5 [14], none of the allelic variants of the genes
controlling their expression has been shown to be quanti-
tatively important with regard to the biotransformation of
the PPIs, with the possible exception of the impact of the
CYP3A5*3/*3 genotype on ilaprazole clearance, as repor-
ted from a cohort of Chinese subjects [13]. This is not the
case for CYP2C19 where genetic polymorphism has been
shown not only to produce large variation in the pharma-
cokinetics of the PPIs but also to be associated with their
pharmacodynamics (i.e., concentration-effect relation-
ships) and drug-interaction potential [15, 16]. Pharmacog-
enomic variability in the constitutive expression of the
enzymes responsible for PPI biotransformation also has
potential implications regarding the stereospecificity of
their metabolism, as has been demonstrated for omeprazole
[17] and lansoprazole [18]. Finally, given the quantitative
predominance of CYP3A and CYP2C19 isoforms in the
liver, hepatic insufficiency significantly prolongs the
plasma clearance of the drug and as a result, increases
systemic exposure (i.e., increased area under the concen-
tration–time curve [AUC]) [19].
2.2 Ontogeny and PPI Disposition
As all of the PPIs are extensively metabolized, differences
in their biotransformation associated with polymorphism of
drug metabolizing enzymes, ontogeny, and concomitant
disease states are the primary drivers for their disposition
characteristics in pediatric patients. A comprehensive
review of PPI pharmacokinetics in children has been pre-
viously published and reflects a synthesis of data available
before 2005, much of it available in older children and
adolescents [3]. In order to supplement these data, we have
summarized the pharmacokinetic data for PPIs obtained
from clinical investigations conducted in neonates
(Table 2) [20–22], infants (Table 3) [23–26], and children
(Table 4) [26–34]. With the exception of omeprazole, the
pharmacokinetics of available PPIs are not concentration
(or dose) dependent. Consequently, any observed differ-
ences in their pharmacokinetics across the continuum of
development would be expected to occur consequent to the
impact of ontogeny on the activity of enzymes responsible
for PPI biotransformation and, in the case of CYP2C19, the
influence of genetic polymorphism on enzyme activity. An
example resides with pantoprazole, the PPI that most
extensively relies upon CYP2C19 (as opposed to CYP3A4)
for its biotransformation (Fig. 2).
Figure 3 illustrates the apparent oral clearance (CL/F) of
pantoprazole in patients from the neonatal period through
adolescence [35]. These data were derived from a series of
clinical trials submitted to the US FDA for approval and
depict information from subjects whose CYP2C19 geno-
type would predict an extensive metabolizer phenotype. As
predicted from previous work examining the develop-
mental expression of human hepatic CYP2C19, which
demonstrated extremely low levels of enzyme activity in
122 R. M. Ward, G. L. Kearns
the first 2 months of postnatal life [36], the CL/F of pan-
toprazole was also lower than that observed in older
infants, children, and adolescents. These data corroborate
previously summarized findings of reduced omeprazole
and lansoprazole plasma clearance in neonates [3]. Previ-
ous studies have reported a trend towards increasing PPI
(omeprazole and lansoprazole) clearance with decreasing
age in childhood and no correlation between age and PPI
pharmacokinetic parameters among children [3]. The CL/F
data from the pediatric studies of pantoprazole (Fig. 3) do
not suggest significant age association, with the exception
of the first 4–5 months of postnatal life, a time where the
correlation between CL/F and age is direct, linear, and
statistically significant (Fig. 4b). It should be noted that the
relationship between pantoprazole CL/F and age over the
first 20 weeks of postnatal life (Fig. 4b) [22] corresponds
dimensionally to the ontogeny of CYP2C19 over this same
period (Fig. 4a) [36]. Thus, the ontogeny of CYP2C19 and
the apparent oral plasma clearance of pantoprazole ‘mirror’
each other and, thereby, validate the predominant role for
this particular CYP isoform in the metabolism of this PPI.
As mentioned previously, polymorphic expression of all
enzymes responsible for catalyzing the biotransformation
of the PPIs can markedly influence their dose versus
exposure versus response relationships. It is now widely
recognized that the CYP2C19 polymorphism is responsible
for the marked variability in the pharmacokinetics, phar-
macodynamics, and drug interaction potential for the PPIs
in adults [15]. Likewise, in pediatric patients, we have
























































































Fig. 2 The metabolic pathways of the proton pump inhibitors and the
major cytochrome P450 (CYP) isoenzymes involved. The thicker the
arrow, the larger the contribution of the CYP isoforms to the
metabolic pathway. Reproduced from Litalien et al. [3], with
permission from Springer International Publishing AG ( Adis Data
Information BV [2005]. All rights reserved.)
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genotype predictive of a poor-metabolizer phenotype have
significantly higher systemic drug exposure (i.e., AUC) and
prolonged plasma drug clearance for both omeprazole [27]
and pantoprazole [31] as compared with individuals with
an extensive and/or intermediate metabolizer phenotype.
Concordance between genotype and phenotype for
Table 2 Pharmacokinetics of proton pump inhibitors in newborn patients from birth to 44 weeks adjusted age (gestational age at
birth ? chronologic age after birth)
Esomeprazole [20] Lansoprazole [21] Pantoprazole [22]
No. of newborns 26 12, 12 19, 21
Gestational age at birth (weeks) 33.3 (23–41) 29 (23.5–40.0), 28 (23.0–41.0)
Fixed dose (mg) 1.25, 2.5
Dose (mg/kg) 0.5, 1.0 0.6 approx., 1.2 approx.
Chronologic age (weeks) 4.1 (1–19), 3.3 (\1–12) 7.7 (1.3–17.7), 8.0 (1.3–19.6)
Adjusted age at study (weeks) 39.8 (35.6–44) 40.4 (35–43), 38.7 (30–44) 37.8 (34.1–43.9), 36.4 (33.3–43.6)
Weight at study (g) 3,339 ± 763, 2,690 ± 926 2,661 ± 586 (2,060–4,100), 2,636 ± 623 (2,018–4,550)
AUC0–? (lgh/mL) 5.09 ± 2.61, 9.37 ± 4.79
AUC (lgh/mL) 3.54 ± 2.82 (80 % CV), 7.27 ± 5.30 (73 % CV)
AUCs (lmolh/mL) 2.5 (0.2–6.6)
tmax (h) 1.65 (0.65–2.25) 3.1 ± 2.2, 2.6 ± 1.5
Cmax (ng/mL) 831 ± 381, 1,672 ± 809
Cmax (lmol/L) 0.74 (0.1–1.5)
CL/F (L/kg h) 0.16 ± 0.18, 0.16 ± 0.15 0.21 ± 0.12 (59 % CV), 0.23 ± 0.21 (92 % CV)
V/F (L) 1.63 (19 % RSE)
Terminal t (h) 2.8, 2.0 3.1 ± 1.5, 2.7 ± 1.1
All values are mean ± standard deviation and/or (range) unless otherwise indicated
Approx. approximately, AUC Area under the concentration–time curve from zero to the last time point measured, AUC0–? area under the
concentration–time curve from time zero to infinity, AUCs area under the concentration–time curve from time zero to a specified time, CL/F
apparent oral clearance, Cmax maximum plasma drug concentration, CV coefficient of variation, RSE relative SE (100 9 SE/estimate), SE
standard error, t elimination half-life, tmax time to maximum concentration, V/F apparent volume of distribution
Table 3 Pharmacokinetics of proton pump inhibitors in infants 1–24 months of age
Omeprazole [23] Esomeprazole [24] Lansoprazole [25] Pantoprazole [26]
Chronologic age (months) 4–27 1–24 13–24 1–11
No. of infants 4, 5 26, 24 5 21, 21
Dose (mg/kg) 0.56 ± 0.04, 1.17 ± 0.08a 0.25, 1 1.4 ± 0.19 0.6 approx., 1.2 approx.
Dose (mg/1.73 m2) 20, 40
Fixed dose (mg) 15 2.5–5, 5–10
AUC0–? (ngh/mL) 1,046 ± 1,043, 3,602 ± 3,269
AUC0–? (lgh/mL) 0.94 ± 0.48, 3.94 ± 2.53a
AUC0–24 (ngh/mL) 1,906 ± 770
AUCs (lmolh/mL) 1.34 ± 1.52, 5.31 ± 5.47
tmax (h) 2.2 ± 1.0, 3.4 ± 1.9 1.4 ± 0.9 1.03 (0.98–11.83), 1.02 (0.5–4.08)
Cmax (ng/mL) 894 ± 345 503 ± 506, 1,318 ± 1,307
Cmax (lmol/L) 0.39 ± 0.48, 1.43 ± 2.15
CL/F (L/kg h) 0.68 ± 0.27, 0.42 ± 0.28a 1.54 ± 2.35, 0.87 ± 1.36
Terminal t (h) 0.9 ± 0.5, 1.0 ± 0.4 0.66 ± 0.30 1.78 ± 1.30, 1.42 ± 0.78
All values are mean ± standard deviation or mean (range), unless otherwise indicated
Approx. approximately, AUC0–? area under the concentration–time curve from time zero to infinity, AUCs area under the concentration–time
curve during a dosing interval, AUC0–24 area under the concentration time for 24 h on treatment day 5, CL/F apparent oral clearance, Cmax
maximum plasma drug concentration, t elimination half-life, tmax time to maximum concentration
a Recalculated from data in Faure et al. [23], Table 2
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CYP2C19 would be expected in children where CYP2C19
has reached adult activity (6–12 months after birth). This
would be reflected in concordance between pharmacoki-
netics and pharmacodynamics for pantoprazole, which is
seen with pantoprazole CL/F (Fig. 3). In contrast, low
constitutive activity of CYP2C19 observed in the first
2 months of life (Fig. 4a) produces a discordance between
genotype and phenotype, as reflected by examination of
pantoprazole CL/F (Fig. 4b).
Finally, interpretation of the intersection of ontogeny
and the CYP2C19 genotype must consider that for this
drug metabolizing enzyme and selected PPIs, an apparent
gene–dose effect exists. In a recent study designed to
examine the impact of the CYP2C19*17 allele on PPI
pharmacokinetics [37], a gene–dose effect was apparent for
pantoprazole when the apparent plasma elimination rate
constant (a pharmacokinetic parameter that should be
independent of absorption) was examined as a function of
CYP2C19 genotype. This same relationship was absent for
omeprazole (Fig. 5). It is possible that this difference
resides with the relative contributions of CYP2C19 and
CYP3A4 in the overall biotransformation of omeprazole as
compared with pantoprazole [38]. Thus, an ontogenic
relationship has been demonstrated for some PPIs, but not
for others. Consequently, even within this relatively
homogeneous drug class, genotype does not always predict
drug disposition.
3 Pharmacodynamics of PPIs in Pediatric Patients
Inhibition of the H?–K?-ATPase proton pump requires
activation of the pump before the PPI is removed from the
circulation, which in turn relates to the rate of absorption,
time to maximum concentration (tmax), and rate of elimi-
nation of the drug from the circulation, which is influenced
by development and genetics. Wide ranges of tmax imply
variable absorption of PPIs among individuals and likely
affect the inhibition of acid secretion. Since gastrin release
after a meal is one of the most potent activators of H?–K?-
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Fig. 3 Association between age and the weight-normalized apparent
oral clearance (CL/F) of pantoprazole in neonates, infants, children,
and adolescents. Dashed lines represent apparent ‘best fit’ from non-
linear (for subjects from birth through 0.5 years of age) and linear (for
subjects from 0.5 to 16 years of age) regressions of the data and are
provided to illustrate association between CL/F and age. Data were
obtained from a series of labeling studies conducted by the study
sponsor and subjected to a population-based pharmacokinetic analysis











































30 38 1 2 3 4 5
Fig. 4 a Association between cytochrome P450 (CYP) 2C19 protein
expression in the human fetus and neonate, shown by dark circles.
Open and grey circles represent outliers based on analysis of residuals
that were not used in the regression analysis [36]. Reproduced from
Koukouritaki et al. [36],  The American Society for Pharmacology
and Experimental Therapeutics 2004, with permission. EGA esti-
mated gestational age, PNA postnatal age. b The association between
postnatal age and the apparent oral clearance (CL/F) of pantoprazole
following a single oral dose of either 1.25 mg (dark circles) or 2.5 mg
(grey circles). Triangles denote patients with a CYP2C19 genotype
that would be predictive of a poor-metabolizer phenotype. A regres-
sion line (p \ 0.05 for r2) is shown to illustrate the association
between CL/F and age. Reproduced from Ward et al. [22],
 Springer-Verlag 2010, with the kind permission of Springer
Science ? Business Media
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before a meal to be absorbed, but not eliminated, by the
time the proton pump is activated. Several pharmacokinetic
studies in Tables 2, 3, and 4 show wide ranges of tmax,
indicating wide variation in absorption, which can lead to
variation in response. After the activated PPI binds to the
H?–K?-ATPase, either reversibly or irreversibly, acid
secretion is inhibited long after the PPI is eliminated from
the circulation. The pump protein has a half-life of around
54 h in rats, which is similar to that in humans [6]. Acid
secretion is inhibited for 24 h after omeprazole and for
46 h after pantoprazole, because of the differences in
binding to the CYSs of the proton pump [6]. Not all pumps
are active and inhibited after the first dose, so steady state
requires around 3 days to develop [7]. Despite this differ-
ence between persistence of drug in the circulation and the
duration of inhibition of acid secretion, pharmacogenetic
studies of serum AUC and acid secretion AUC in patients
with allelic variants for CYP2C19 showed a potential
relationship between systemic drug exposure and gastric
pH (Kearns et al., unpublished data).
3.1 Newborn Gastric Acid Secretion
At birth, premature newborns at 24 weeks gestation have
the capacity to secrete enough acid to maintain a basal
gastric pH of\4, but the volume of acid secreted does not
reach adult levels for 5–6 months after birth [39]. The
volume of gastric acid that is released after stimulation
relates to the parietal cell mass and does not reach adult
levels until 5–6 months after birth [39]. Although it would
seem logical that a smaller parietal cell mass would require
smaller doses of a PPI for inhibition, that is not the case, or
at least that is not current practice. When the current
neonatal and infant doses of PPI are compared with the
capacity for acid secretion in milliEquivalents, these doses
are 7-fold to 9-fold higher than the doses that are effective
for treatment of adults. The dose-related duration of proton
pump inhibition in newborns has not been described, but
might support lower and less frequent dosing than is cur-
rently practiced. The pharmacodynamics among different
PPIs needs more study in neonates.
3.2 Treatment of Newborns with PPIs
The pharmacodynamics of PPIs in preterm and term
newborns have not received as much study as they have
in older pediatric populations, because of the challenges in
studying this population. Most of the studies of PPIs in
newborns have been stimulated by the Best Pharmaceuti-
cals for Children Act, which provides an extension of
market exclusivity in return for completion of studies
specified in a Written Request by the FDA [40–43]. The
Written Request specifies the study design, including the
ages of patients, size of study population, and the mea-
surements to be completed. Omeprazole was evaluated in a
double-blind, randomized, crossover study that measured
the effect of a 0.7 mg/kg dose administered once daily in
ten newborns at 34–40 weeks postmenstrual age [44]. Both
esophageal pH and gastric pH were increased after 1 week
of treatment. The percentage of time that gastric pH was
\4 was inversely related to the plasma omeprazole con-
centration measured 2 h after the dose. Pantoprazole
studied in the newborn showed that a 1.2 mg/kg daily dose
raised gastric pH, but not esophageal pH, although the
normalized AUC of esophageal H? was significantly
reduced [45]. Just as importantly, the percentage of patients
with a normal reflux index of \5 % was not changed











































Fig. 5 Relationship between cytochrome P450 2C19 genotype and
the apparent terminal elimination rate constant (Kel) for pantoprazole
in children and adolescents. Boxes reflect interquartile range, lines in
the boxes depict the mean values, and whiskers indicate the 10th and
90th percentiles, respectively. For the pantoprazole data, horizontal
lines above the boxes join genotype groups that are not significantly
different from each other as determined by Tukey’s honestly
significant difference test after an initial ANOVA. Reproduced from
Kearns et al. [37],  The American Society for Pharmacology and
Experimental Therapeutics 2010, with permission
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preterm and term newborns at postmenstrual ages of
35.6–44 weeks for 7 days were similar [20]. Esomeprazole
raised gastric pH and the percentage of time gastric pH was
[4. It reduced the percentage of time the esophageal pH
was \4, the number of reflux events, and the number of
acid reflux episodes[5 min. Despite this inhibition of acid
production and acid reflux, reflux episodes measured by
impedance did not decrease. Thus, inhibition of acid pro-
duction by PPIs for treatment of newborns will only be
beneficial if they have acid-related problems, such as
esophagitis or upper airway inflammation. Clinicians will
recognize that such problems do occur in newborns, but
they are difficult to diagnose accurately, and clinical signs
such as apnea are not valid indicators of reflux.
3.3 Treatment of Infants\12 Months of Age with PPIs
In infants of 1–11 months of age, PPIs demonstrate sig-
nificant inhibition of gastric acid secretion and reduce acid
reflux. Pantoprazole demonstrated a dose response with
significantly more inhibition of acid secretion with 1.2 mg/
kg than with 0.6 mg/kg dosing [45]. The 1.2 mg/kg dose
reduced gastric H? AUC and esophageal H? AUC, but this
dose paradoxically lowered mean (± standard deviation)
esophageal pH from 5.2 ± 0.4 to 4.9 ± 0.3. Possibly due
to the smaller parietal cell mass in the newborn, pantop-
razole doses of 1.2 mg/kg (high dose) raised gastric pH
above 4 for 79 % of the day in newborns and for 57 % of
the day in infants at 1–11 months of age. Esomeprazole in
a larger age range of 1–24 months demonstrated a favor-
able dose-response from 0.25 mg/kg to 1 mg/kg, with the
larger dose increasing the percentage of time the gastric pH
was [4 and reducing the percentage of time the intra-
esophageal pH was \4 [44].
Until the recent labeling of esomeprazole for erosive
esophagitis in 1–11 month old infants, the effectiveness of
the PPIs in infants and newborns for reduction of esopha-
gitis and gastroesophageal reflux disease (GERD) had not
been established. Many pediatric clinical studies of the
effectiveness of PPIs have occurred in response to Written
Requests from the FDA for studies to qualify for Pediatric
Exclusivity through the Food and Drug Administration
Modernization Act of 1997, the Best Pharmaceuticals for
Children Act of 2002, and the Food and Drug Adminis-
tration Amendments Act of 2007 [46–48]. Some study
designs, particularly those relating to infants that involved
a ‘run-in’ treatment period followed by blinded treatment
withdrawal have been criticized because of the potential for
hypergastrinemia to overstimulate gastric acid secretion
when the PPI is stopped. Furthermore, the effectiveness of
PPI treatment of newborns remains controversial primarily
because of uncertainty about how to measure reflux
associated disorders, such as esophagitis, laryngitis, or
aspiration. Endoscopy and biopsies are not routinely per-
formed in neonates suspected of esophagitis, so assessment
has relied on symptom assessment.
The initial Written Requests for studies of efficacy of
PPIs in neonates issued by the FDA requested analysis
of obstructive apnea as an index of symptomatic reflux
[40–43]. Unfortunately, pH probe studies combined with
measures of apnea have shown a low temporal correlation
between gastroesophageal reflux and apnea [49–51]. Fur-
thermore, studies of the rate of apnea before and during
treatment with PPIs have not shown a reduction in apnea
[52]. This endpoint was later eliminated from the PPI
Written Requests, and no efficacy studies were required by
the FDA in neonates to qualify for Pediatric Exclusivity
[53–56]. Orenstein et al. [57] conducted a randomized,
blinded, placebo-controlled study of lansoprazole treatment
of gastroesophageal reflux (GER) in newborns. They found
no improvement in symptom scores between neonates who
received placebo and those treated with lansoprazole, but
response was defined as a 50 % reduction in the specific
symptom. Treatment was confounded by non-pharmaco-
logic management of GER that was continued in 63 % of
patients at the investigator’s discretion [57]. Placebo-con-
trolled studies of GERD in newborns and infants without
the confounding influence of other simultaneous treatments
for GERD are still needed. Until that occurs, the contro-
versies about whether acid-related problems occur in
newborns or not will continue [58, 59].
Except for the recent labeling of esomeprazole for
1–11 month old infants, studies of PPIs in infants had also
failed to demonstrate efficacy. The study design by Winter
et al. [60] for pantoprazole is one recommended by the
FDA to qualify for Pediatric Exclusivity. This study
enrolled infants with GERD at 31 sites who were identified
by a symptom score or endoscopic evidence of esophagitis.
For 2 weeks, they received non-PPI therapy of thickened
hypoallergenic feedings (if not breast fed), positioning,
environmental modification, and antacids as needed.
Infants who were still symptomatic after 2 weeks were
treated with pantoprazole approximately 1.2 mg/kg/day for
4 more weeks. At that point, a blinded substitution of
placebo for pantoprazole began in half of the patients. The
endpoint of the study was the percentage of patients with
worsening of GERD by symptoms, endoscopic study, or
maximal use of antacids during the 4-week, double-blind,
randomized withdrawal phase. Although there was a sig-
nificant decrease in symptom scores during the open-label
treatment phase, no differences were detected in the rate of
study withdrawal between the pantoprazole-treated and
placebo-treated groups during the double-bind PPI with-
drawal. Several possible explanations could be considered.
It is possible that esophagitis does not occur at these ages,
but many pediatric gastroenterologists and pediatricians
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find that inaccurate. It might be that only a small per-
centage of infants with GER develop GERD. It is also
possible that the study design was unable to detect a change
in esophagitis primarily on the basis of symptoms. Possi-
bly, the esophagitis was healed during the 4-week, open-
label treatment. At enrollment, only 35 of 106 symptomatic
patients had some type of test performed for GERD. Of
those having a test, 66 % were consistent with GERD. The
study did not require endoscopy in all patients, and there
was no follow-up endoscopy at the end of study, creating
uncertainty about the diagnosis.
3.4 Treatment of Children Older than 1 Year of Age
with PPIs
In pediatric patients older than 1 year of age, many studies
have shown PPIs to be effective for treatment of erosive
esophagitis diagnosed by history, endoscopy, and biopsy
and for treatment of Helicobacter pylori. Extensive reviews
of reported pediatric studies of PPIs have been reported.
Earlier reviews reported on omeprazole 0.7–3.5 mg/kg/
day, lansoprazole 0.73–1.5 mg/kg/day [4] and omeprazole
0.3–3.3 mg/kg/day [61]. Rather than repeat this work, we
refer the reader to those reviews along with additional
reviews that have expanded the list of PPIs to include
pantoprazole, esomeprazole, and rabeprazole [62–66].
4 Prolonged Treatment of Pediatric Patients
Prolonged inhibition of the proton pump has raised concerns
among gastroenterologists and regulators at the FDA. Long-
term inhibition of gastric acid secretion leads to prolonged
hypergastrinemia and concerns for enterochromaffin-like cell
hyperplasia, carcinoid formation, vitamin B12 deficiency,
hypomagnesemia, necrotizing enterocolitis, osteoporosis,
atrophic gastritis, and increased infections [67]. These con-
cerns have been raised in adults, but pediatric studies are
limited. Tolia and Boyer [67] reported the outcomes of
32–47 months of treatment with PPIs in 133 pediatric patients
ranging in age from 0.1 to 17.6 years at the start of treatment.
The frequency of use of PPIs was lansoprazole [ omepra-
zole [ pantoprazole [ esomeprazole[ rabeprazole. Most
patients were dosed twice a day. Parietal cell hyperplasia was
observed in 0–16 % of patients during follow-up, but inter-
estingly, the gastric histology was normal significantly more
often when treatment continued for longer than 48 months
and when patients were treated with higher doses. Gastrin
levels were elevated to[90 pg/mL in 73 % of the children,
but vitamin B12 remained normal.
5 Summary
Several aspects of the pharmacology and treatment of
children with PPIs should be considered to optimize
treatment of pediatric patients with acid-related disorders.
• Without activation through ligand binding by hista-
mine, gastrin, acetyl choline, or other mediators, the
parietal cell acid pump (H?–K?-ATPase) is inactive
and cannot be inhibited.
• H?–K?-ATPase must be activated to secrete gastric
acid, which is needed for the PPI to be activated in
order to bind to the enzyme to cause inhibition.
• The pharmacokinetics of the PPIs, especially the
absorption rate and tmax, must be considered in
the dosing schedule for a PPI so it is present in the
circulation when the proton pump is active. This usually
requires administration of the PPI 60–90 min before a
meal.
• The site of binding of the different activated PPIs to
different CYSs in the H?–K?-ATPase influence the
reversibility of the proton pump inactivation and the
duration of inhibition.
• For children older than 1 year, the pharmacodynamics
of PPIs for treatment of peptic acid disorders, such as
erosive esophagitis and peptic ulcer disease, are similar
to that in adults.
• Except for the recent labeling of esomeprazole, efficacy
of PPI treatment of newborns and infants through
11 months of age for GERD has not been demonstrated,
despite inhibition of gastric acid secretion. This may
relate to difficulties in determining what clinical signs
relate to esophagitis and which do not in this preverbal
population or to a lack of gastric acid-mediated disease.
Clinicians are divided on this last issue between those
who believe gastric acid-mediated disease does occur in
newborns and infants and those who do not.
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